Search

Your search keyword '"Venissac N"' showing total 254 results
Start Over Author "Venissac N"
254 results on '"Venissac N"'

2. Prise en charge diagnostique et thérapeutique du mésothéliome pleural en 2024

Author

Scherpereel, A., Venissac, N., Humez, S., Ulmer, L., Locatelli-Sanchez, M., Brosseau, S., Dhalluin, X., Nunes, D., Gounant, V., Lantuejoul, S., and Zalcman, G.

Abstract

Le mésothéliome pleural (MP) est un cancer assez rare, classiquement secondaire à une exposition antérieure à l’amiante. Son pronostic reste globalement mauvais, sans traitement curatif validé à ce jour. La thoracoscopie avec biopsies pleurales (± une symphyse pleurale d’emblée) est l’examen diagnostique clé. La chirurgie, intégrée à un traitement multimodal et d’indication très restreinte à des patients hyper-sélectionnés, est à nouveau remise en cause récemment. En première ligne de traitement, la chimiothérapie standard à base de pemetrexed et sels de platine a vu son efficacité améliorée par l’association avec le bevacizumab. Mais elle est concurrencée par la double immunothérapie Nivolumab + Ipilimumab particulièrement dans les formes non-épithélioïdes, et bientôt peut-être par des associations chimiothérapie + immunothérapie. Aucun traitement standard n’est validé en deuxième ligne ou plus, même si les anticorps anti-PD-1 /PD-L1 ± anti-CTLA-4 ont aussi montré des résultats intéressants en essais cliniques de phase II et III. La recherche de nouveaux traitements, stratégies et biomarqueurs est donc cruciale et l’inclusion des patients en essai clinique fortement encouragée. D’autres immunothérapies seules ou en combinaison avec des traitements standards et/ou thérapies ciblées, des stratégies multimodales sont actuellement évaluées. En France, le réseau national INCades centres experts pour la prise en charge du MP « NETMESO » vise à proposer une prise en charge optimale à tout patient systématiquement discuté en RCP régionale (± nationale) dédiée, et à stimuler la recherche clinique et translationnelle en collaboration avec ses partenaires dont les associations de patients.

Published
2024
Full Text
View/download PDF

4. Endométriose thoracique en Martinique

Author

Agossou, M., primary, Gilbert-Sanchez, B., additional, Alauzen, P.H., additional, Maud, O., additional, Cecilia-Joseph, E., additional, Chevalier, L., additional, Jean-Laurent, M., additional, Dramé, M., additional, and Venissac, N., additional

Published
2024
Full Text
View/download PDF

18. Multicentre study of neoadjuvant chemotherapy for stage I and II oesophageal cancer

Author

Bekkar, S., Gronnier, C., Renaud, F., Duhamel, A., Pasquer, A., Théreaux, J., Gagnière, J., Meunier, B., Collet, D., Mariette, C., Dhahri, A., Lignier, D., Cossé, C., Regimbeau, J.-M., Luc, G., Cabau, M., Jougon, J., Badic, B., Lozach, P., Bail, J. P., Cappeliez, S., El Nakadi, I., Lebreton, G., Alves, A., Flamein, R., Pezet, D., Pipitone, F., Stan-Iuga, B., Contival, N., Pappalardo, E., Coueffe, X., Msika, S., Mantziari, S., Demartines, N., Hec, F., Vanderbeken, M., Tessier, W., Briez, N., Fredon, F., Gainant, A., Mathonnet, M., Bigourdan, J. M., Mezoughi, S., Ducerf, C., Baulieux, J., Mabrut, J.-Y., Baraket, O., Poncet, G., Adam, M., Vaudoyer, D., Enfer, P. Jourdan, Villeneuve, L., Glehen, O., Coste, T., Fabre, J.-M., Marchal, F., Frisoni, R., Ayav, A., Brunaud, L., Bresler, L., Cohen, C., Aze, O., Venissac, N., Pop, D., Mouroux, J., Donici, I., Prudhomme, M., Felli, E., Lisunfui, S., Seman, M., Petit, G. Godiris, Karoui, M., Tresallet, C., Ménégaux, F., Vaillant, J.-C., Hannoun, L., Malgras, B., Lantuas, D., Pautrat, K., Pocard, M., Valleur, P., Lefevre, J. H., Chafai, N., Balladur, P., Lefrançois, M., Parc, Y., Paye, F., Tiret, E., Nedelcu, M., Laface, L., Perniceni, T., Gayet, B., Turner, K., Filipello, A., Porcheron, J., Tiffet, O., Kamlet, N., Chemaly, R., Klipfel, A., Pessaux, P., Brigand, C., Rohr, S., Carrère, N., Da Re, C., Dumont, F., Goéré, D., Elias, D., and Bertrand, C.

Published
2016
Full Text
View/download PDF

28. Évaluation de la VNI préopératoire en chirurgie thoracique carcinologique, étude randomisée contrôlée PREOVNI-GFPC 12,01

Author

Paleiron, N., primary, Grassin, F., additional, Lancelin, C., additional, Tromeur, C., additional, Margery, J., additional, Berard, H., additional, Cuvelier, A., additional, Egenod, T., additional, Vinas, F., additional, Gagnadoux, F., additional, Venissac, N., additional, Donzel-Raynaud, C., additional, Kerjouan, M., additional, Falchero, L., additional, Le Treut, J., additional, Tiffet, O., additional, Pichon, I., additional, Dion, A., additional, Leroyer, C., additional, Descourt, R., additional, and Couturaud, F., additional

Published
2019
Full Text
View/download PDF

31. Video-mediastinoscopy in Management of Patients With Lung Cancer: A Preliminary Study

Author

Venissac, N., Alifano, M., Karimdjee, B. S., Guillot, F., Rabary, O., and Jérôme Mouroux

Subjects
Male, Lung Neoplasms, Mediastinoscopy, Mediastinoscopes, Video-Assisted Surgery, Adenocarcinoma, Middle Aged, Carcinoma, Squamous Cell, Humans, Female, Surgery, Carcinoma, Small Cell, Aged, Neoplasm Staging
Abstract

Cervical mediastinoscopy is widely employed for biopsy of mediastinal lymph nodes and staging of lung cancer. The application of video-assisted technology to mediastinoscopy in a series of patients with lung cancer has not been reported. Preliminary experience with the use of video-mediastinoscopy in diagnosis and staging of lung cancer is presented. Fifteen patients with lung cancer were studied. Results of previous computed tomography scans had shown the presence of enlarged mediastinal lymph nodes in the retrovascular plane in all of the cases. Video-mediastinoscopy was performed under general anesthesia using a specifically designed rigid scope connected to a mono-charged-coupled device video camera (model INH 002756; Karl Storz-Endoskope, Tuttlingen, Germany). Neither fatalities nor major complications related to the procedure were observed. In all cases, video-mediastinoscopy proved useful for diagnosis or staging of lung cancer, therefore contributing to clinical decision making. The optimal visualization of mediastinal structure and the possibility for the surgeon to operate with both hands are appreciable characteristics of this technique.

Published
2000
Full Text
View/download PDF

33. Impact of Kras mutant subtypes on PD-L1 expression in lung adenocarcinoma

Author

Falk, A.T., primary, Yazbeck, N., additional, Thon, L., additional, Guibert, N., additional, Hofman, V., additional, Zahaf, K., additional, Lespinet, V., additional, Bordone, O., additional, Tanga, V., additional, Washetine, K., additional, Cohen, C., additional, Venissac, N., additional, Mouroux, J., additional, Marquette, C.-H., additional, Brest, P., additional, Ilié, M., additional, and Hofman, P., additional

Published
2016
Full Text
View/download PDF

36. [Evaluation of preoperative non-invasive ventilation in thoracic surgery for lung cancer: the preOVNI study GFPC 12-01]

Author

Paleiron, Nicolas, André, Michel, Grassin, F., Chouaïd, C., Venissac, N., Margery, J., Couturaud, Francis, Noël-Savina, Elise, Tromeur, Cécile, Vinsonneau, U., Vedrine, L., Leroyer, Christophe, Nowak, Emmanuel, Berard, H., Thomas, P., Brouchet, L., Bagan, P., Fournel, P., Mottier, Dominique, Robinet, Gilles, Service de Pneumologie (HIA BREST - Pneumologie), Hôpital d'Instruction des armées, Service de Pneumologie (CRETEIL - Pneumologie), CHI Créteil, Service de Chirurgie Thoracique (NICE - Chirurgie Thoracique), Centre Hospitalier Universitaire de Nice (CHU Nice), Service de Pneumologie (HIA PERCY - Pneumologie), HIA Percy, Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Service de Cardiologie (HIA BREST - Cardio), HIA - BREST, Service d'Oncologie (HIA VAL DE GRACE - Oncologie), HIA VAL DE GRACE, Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Pneumologie (HIA TOULON - Pneumologie), Hopital d'instruction des armées Sainte-Anne [Toulon] (HIA), Service de Pneumologie (GAP - Pneumologie), CHICAS - GAP, Service de Chirurgie Thoracique (TOULOUSE - Chirurgie Thoracique), CHU Toulouse [Toulouse], Service de Chirurgie Thoracique (ARGENTEUIL - Chirurgie Thoracique), CH Argenteuil, Service d'Oncologie Thoracique (SAINT ETIENNE - Oncologie Thoracique), Institut Cancérologique de la Loire, and Service d'Oncologie Thoracique (BREST - ICH)

Subjects
MESH: Preoperative Care, MESH: Humans, MESH: Heart Diseases, MESH: Pneumonectomy, [SDV]Life Sciences [q-bio], MESH: Adult, MESH: Prospective Studies, MESH: Lung Neoplasms, MESH: Positive-Pressure Respiration, MESH: Randomized Controlled Trials as Topic, MESH: Postoperative Complications, MESH: Obesity, MESH: Patient Selection, MESH: Carcinoma, Non-Small-Cell Lung, MESH: Sample Size, MESH: Noninvasive Ventilation
Abstract

International audience; BACKGROUND: Surgical resection is the best treatment for stage I and II non-small cell lung cancer. Despite an improvement in the perioperative management of cancer patients and specialization of surgical teams, morbidity and mortality remains significant. Non-invasive ventilation (NIV) is an effective therapeutic option in hypercapnic respiratory failure. It also improves functional and gasometric parameters when undertaken before surgery. The objective of the preOVNI study is to demonstrate that preoperative non-invasive ventilation for 7 days, at home, reduces the postoperative respiratory and cardiovascular complications of lung resection surgery, in a high-risk population. METHODS: A prospective, randomized, controlled open-labelled multicentric French study, under the supervision of the Groupe Français de Pneumocancérologie (GFPC), comparing 7 days of preoperative non-invasive ventilation with standard treatment. Inclusion criteria are: patients suitable for lobectomy or segmentectomy for primary bronchial carcinoma and presenting with obstructive or restrictive lung disease, obesity or chronic cardiac insufficiency. The primary criterion is a composite one, including all respiratory and cardiac complications. The number of patients is 150 in each treatment arm, 300 in total. EXPECTED RESULTS: We think that preoperative NIV will be able to reduce the rate of postoperative complications. If this objective is achieved, the management of these patients could be changed.

Published
2013
Full Text
View/download PDF

41. Detection of Circulating Tumor Cells from Lung Cancer Patients in the Era of Targeted Therapy : Promises, Drawbacks and Pitfalls

Author

Hofman, V., primary, Ilie, M., additional, Long, E., additional, Guibert, N., additional, Selva, E., additional, Washetine, K., additional, Mograbi, B., additional, Mouroux, J., additional, Venissac, N., additional, Reverso-Meinietti, J., additional, Milano, G., additional, Mazieres, J., additional, Marquette, C.-H., additional, Paterlini-Brechot, P., additional, and Hofman, P., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results